Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.73 |
| ▸ | MMP13 | P45452 | 4/20 | 0.66 |
| ▸ | MMP14 | P50281 | 4/20 | 0.66 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.66 |
| ▸ | MMP7 | P09237 | 1/20 | 0.66 |
| ▸ | MMP12 | P39900 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618630 | 0.91 | MMP2 (0.84) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3616996 | 0.91 | MMP2 (0.84) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3615848 | 0.90 | MMP2 (0.71) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3607878 | 0.90 | MMP2 (0.78) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3605086 | 0.90 | MMP2 (0.78) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3618988 | 0.90 | MMP2 (0.78) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3612686 | 0.90 | MMP2 (0.78) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3612688 | 0.90 | MMP2 (0.78) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3613967 | 0.87 | MMP2 (0.73) | MMP2MMP13MMP14ADAMTS4MMP7 | |
| SCHEMBL3616183 | 0.85 | MMP2 (0.76) | MMP2MMP13MMP14ADAMTS4MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | claimed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | MMP2 5/4885MMP13 13/4885MMP14 19/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | MMP2 5/4885MMP13 13/4885MMP14 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.